Culshaw Geoff J, MacIntyre Iain M, Dhaun Neeraj, Webb David J
University/British Heart Foundation Centre for Cardiovascular Science, Queen's Medical Research Institute, University of Edinburgh, 47 Little France Crescent, Edinburgh, EH16 4TJ, Scotland, UK.
University/British Heart Foundation Centre for Cardiovascular Science, Queen's Medical Research Institute, University of Edinburgh, 47 Little France Crescent, Edinburgh, EH16 4TJ, Scotland, UK.
Semin Nephrol. 2015 Mar;35(2):176-87. doi: 10.1016/j.semnephrol.2015.03.002.
The incidence and prevalence of chronic kidney disease (CKD) is increasing. Despite current therapies, many patients with CKD have suboptimal blood pressure, ongoing proteinuria, and develop progressive renal dysfunction. Further therapeutic options therefore are required. Over the past 20 years the endothelin (ET) system has become a prime target. Experimental models have shown that ET-1, acting primarily via the endothelin-A receptor, plays an important role in the development of proteinuria, glomerular injury, fibrosis, and inflammation. Subsequent animal and early clinical studies using ET-receptor antagonists have suggested that theses therapies may slow renal disease progression primarily through blood pressure and proteinuria reduction. This review examines the current literature regarding the ET system in nondiabetic CKD.
慢性肾脏病（CKD）的发病率和患病率正在上升。尽管有当前的治疗方法，但许多CKD患者的血压仍不理想，蛋白尿持续存在，并出现进行性肾功能障碍。因此，需要更多的治疗选择。在过去20年中，内皮素（ET）系统已成为主要靶点。实验模型表明，主要通过内皮素-A受体起作用的ET-1在蛋白尿、肾小球损伤、纤维化和炎症的发展中起重要作用。随后使用ET受体拮抗剂的动物和早期临床研究表明，这些治疗可能主要通过降低血压和蛋白尿来减缓肾脏疾病的进展。本综述探讨了有关非糖尿病CKD中ET系统的当前文献。
